Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Barnett Kantz

Internal Medicine Dundee, MI Doctor of Osteopathy

NPI 1275509432 CMS profile 103186

100 Powell Dr., Suite #2, Dundee, MI 48131

Open in the dashboard

General payments

$10,336

643 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Barnett Kantz of Dundee, MI is reported in the CMS Open Payments database as having received $10,336 across 643 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,038 106
2024 General $1,675 91
2023 General $1,871 124
2022 General $1,459 92
2021 General $1,562 111
2020 General $1,089 76
2019 General $642 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Barnett Kantz
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Barnett Kantz were reported at $2,038. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Barnett Kantz Internal Medicine median Middle half National median
2019 $642 $159 $48–$570 $163
2020 $1,089 $119 $33–$402 $114
2021 $1,562 $135 $37–$521 $132
2022 $1,459 $141 $42–$496 $149
2023 $1,871 $149 $45–$519 $160
2024 $1,675 $154 $47–$537 $164
2025 $2,038 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,297 85 payments
  2. AstraZeneca Pharmaceuticals LP $1,264 67 payments
  3. Pfizer Inc. $1,024 75 payments
  4. Lilly USA, LLC $879 56 payments
  5. AbbVie, Inc. $876 59 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $703 45 payments
  7. GlaxoSmithKline, LLC. $598 40 payments
  8. Axsome Therapeutics, Inc. $357 16 payments
  9. Exact Sciences Corporation $325 15 payments
  10. Janssen Pharmaceuticals, Inc $319 18 payments
  11. Other $2,694 167 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,272 640 payments
  2. Education $64 3 payments
Products named General payments · program years 2019–2025
  1. Ozempic $545 39 payments
  2. RYBELSUS $509 36 payments
  3. FARXIGA $493 28 payments
  4. NURTEC ODT $470 30 payments
  5. VRAYLAR $437 28 payments
  6. BREZTRI $406 20 payments
  7. AIRSUPRA $375 16 payments
  8. JARDIANCE $371 26 payments
  9. SHINGRIX $332 23 payments
  10. Auvelity $324 14 payments
  11. Other $9,450 607 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 133 drugs

Part D claims

6,757

Median for Internal Medicine: 777

Drug cost

$641,762

Median for Internal Medicine: $73,373

Branded share of claims

22.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 91 $113,191
Eliquis Apixaban Brand 88 $87,684
Ozempic Semaglutide Brand 28 $54,380
Tradjenta Linagliptin Brand 56 $51,567
Trulicity Dulaglutide Brand 23 $46,747
Mounjaro Tirzepatide Brand 26 $43,823
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 43 $35,700
Xarelto Rivaroxaban Brand 23 $30,676
Farxiga Dapagliflozin Propanediol Brand 19 $21,624
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 19 $13,071

The 10 drugs with the highest cost, of 133 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$47,117

Of which drugs: $12,484

Medicare patients

167

Average age 71

Services billed

590

89 women, 78 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 37%
Ischemic heart disease 23%
Chronic kidney disease 23%
Diabetes 22%
Depression 18%
Heart failure 16%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 26 26 $7,484
Vaccine for influenza for injection into muscle 90653 Office 21 21 $1,718

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $195
$195 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $183
$183 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $54
  • Lilly USA, LLC $49
$103 91 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $88
$88 — —
AREXVY
  • GlaxoSmithKline, LLC. $84
$84 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

643 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record